lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· March 16, 2026

Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

View original at finance.yahoo.com
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clea…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The topline results from ADorable-1 offer hope for young patients, delivering near-complete skin clearance and significant itch relief with a highly selective medicine that targets the underlying inflammation

    60% confidence
  • The safety of EBGLYSS was consistent with the known profile in adult and adolescent patients, with no new safety signals observed in ADorable-1

    60% confidence
  • Lilly plans to submit ADorable-1 data to U.S. and global regulators for a potential label update

    60% confidence
  • Infants and young children with moderate-to-severe atopic dermatitis have fewer approved treatment options than adults and adolescents

    60% confidence
  • EBGLYSS has already changed what's possible for adults and adolescents, delivering durable results that help patients flare less with the option of monthly maintenance dosing

    60% confidence
  • Atopic dermatitis affects 9.6 million children in the U.S., one-third of whom have moderate-to-severe disease

    60% confidence
  • IL-13 is a primary cytokine in atopic dermatitis, driving the type-2 inflammatory cycle in the skin, leading to skin barrier dysfunction, itch, skin thickening and infection

    60% confidence
  • Additional results from ADorable-1 and ADorable-2 will be disclosed later this year

    60% confidence
  • Children with moderate-to-severe atopic dermatitis often endure relentless skin flares, itch and discomfort that can disrupt play, school and daily life for patients and caregivers

    60% confidence
  • EBGLYSS is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

    60% confidence
  • Lilly has coverage with all three major national pharmacy benefit managers and 94% of commercially insured patients have coverage through national health plans

    60% confidence
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis: Source | Via News | fr.via.news